The specific aims of this core have been modified to better serve the needs of the various projects included in the modified program.
Our Aims are: 1) To apply standardized criteria for diagnostic classification of ovarian tumors from patients enrolled in investigational protocols; 2)To provide resources for immunohistochemical evaluation of ovarian carcinomas and the creation ovarian carcinoma tissue microarrays to facilitate the identification of potential therapeutically and diagnsostically relevant targets in human and mouse tissue using immunohistochemistry; 3) To develop and validate methods to characterize eligibility for and responses to targeted therapy; 4) To support the tumor tissue bank as a resource of project investigators. Since the last application, we have added a second Gynecologic Pathologist, Dr Carmen Tornos, as a participant in the program. We have moved all of the mouse pathology activities into this core. The use of our expertise in immunohistochemistry will become increasingly important as we investigate both cell surface targets and cellular signal transduction molecules in the new application. The use of tissue microarrays will allow us to develop efficient, high throughput analysis of dozens of ovarian cancer samples as we seek to validate new targets in large panels of ovarian cancer samples. The analysis of secondary debulkings and core biopsies of recurrent cancers will also allow us to ascertain the efficacy of immune targeting to eliminate specific surface epitopes from the cancer cell population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-15
Application #
7439237
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
15
Fiscal Year
2007
Total Cost
$166,013
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24
Iasonos, Alexia; Sabbatini, Paul; Spriggs, David R et al. (2012) Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 22:63-9
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20

Showing the most recent 10 out of 109 publications